Ikena Oncology (NASDAQ:IKNA - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Ikena Oncology to post earnings of ($0.21) per share for the quarter.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. On average, analysts expect Ikena Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Ikena Oncology Stock Up 5.1 %
Shares of IKNA traded up $0.06 during mid-day trading on Friday, reaching $1.14. 63,892 shares of the stock traded hands, compared to its average volume of 169,419. The firm has a market cap of $54.77 million, a price-to-earnings ratio of -0.92 and a beta of 0.47. The stock has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.46. Ikena Oncology has a 12-month low of $0.97 and a 12-month high of $1.94.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Articles

Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.